The efficacy of Flupentixol melitracen combined with anti-ischemic for treating with anxiety and depression for the patients with coronary artery disease its impact on quality of life
Objective: The efficacy of Flupentixol melitracen (Deanxit) combined with anti-ischemic for treating with anxiety and depression for the patients with coronary artery disease its impact on quality of life. Methods:96 cases with coronary heart disease associated with anxiety and depression were randomly divided into two groups, the study group (48 cases) was given Deanxit combined with anti-ischemic while the control group (48 cases) was treated with anti-ischemic. The clinical efficacy was observed after 4 weeks, while the anxiety self-rating scale and self-rating depression scale scores were observed. After Six months, the quality of life was assessed. Results:The total effective rate of angina improving in the study group was 91.7% significantly higher than 72.9% of the control group (P<0.05); the total effective rate of ECG improving in the study group was 89.6% significantly higher than 60.4% of the control group (P<0.05 ). After the treatment, the anxiety self-rating scale and self-rating depression scale scores of the study group were significantly lower pre-treatment and the control group (P<0.05). The assessment questionnaire scores for quality of life in the study group were significantly higher than those in the control group (P<0.05). Conclusion: Deanxit combined with the conventional treatment for treating with coronary artery disease for the patients with anxiety and depression can significantly improve the anxiety, depression, and improve quality of life, which is worth to be promoted.
coronary heart diseaseDeanxitanxietydepressionquality of life
NETL
NSTL
万方数据
